EXEL News and Press, Exelixis Inc. From 08/01/23

2023-08-01 16:11:41 ET Exelixis press release ( NASDAQ: EXEL ): Q2 Non-GAAP EPS of $0.31 beats by $0.09 . Revenue of $469.85M (+12.0% Y/Y) beats by $25.02M . 2023 Outlook: Total revenues $1.775 billion - $1.875 billion; Net product revenues $1.575 billion -...

- Total Revenues of $469.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $409.6 million - - GAAP Diluted EPS of $0.25, Non-GAAP Diluted EPS of $0.31 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (Nasdaq: EXEL) tod...

2023-07-31 17:35:53 ET Exelixis ( NASDAQ: EXEL ) is scheduled to announce Q2 earnings results on Tuesday, August 1st, after market close. The consensus EPS Estimate is $0.22 (-21.4% Y/Y) and the consensus Revenue Estimate is $444.83M (+6.1% Y/Y). Over the last 2 years,...

2023-07-29 09:08:21 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As biotech stock prices have fallen, Wall Street and biotech boards have grown increasingly unfriendly. Amid the turmoil, key biotech stocks have become the targets of activist investors de...

2023-07-27 07:30:00 ET Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave. And while there are plenty of options on the market, looking at the h...

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (collectively Teva). This settlement resolves patent litigation brought by Exelixis in response to...

2023-07-20 08:08:14 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The biotechnology sector is the reason why treatments and diagnostics for all mankind have experienced exponential advances. If you are passionate about value investing, you must understand tha...

– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2023 financial results will be released on Tuesday, August 1, 2023 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...

2023-07-18 02:00:00 ET Summary Exelixis, an oncology-focused company, has reported a sixth consecutive profitable year in 2022, with about 30% revenue growth due to increased sales of its drug, cabozantinib. EXEL reported total revenues of $408.8 million in Q1 2023, up from $356.0...

2023-07-17 17:51:33 ET Summary Markets roared ahead by over two percent on the week on the back of softer than expected June CPI and PPI reports. Investors are signaling they believe the Federal Reserve will achieve the much hoped for "soft landing." There are two good reasons...